A second generation of senotherapies: the development of targeted senolytics, senoblockers and senoreversers for healthy ageing
Biochemical Society Transactions · 28.08.2024 · 52 (4) · 1661-1671
DOI: 10.1042/bst20231066 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, online erschienen am 28.06.2024. Verfasst von Vinesh Dhokia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mechanisms of Cancer and Ageing Laboratory, Barcelona, Spain. Hauptthemen laut MEDLINE: Senotherapeutics, Cellular Senescence, Healthy Aging. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 85 Literaturangaben.
Abstract (Originalsprache)
Cellular senescence, a form of terminal cell cycle arrest, is as a key driver of organismal ageing and an important factor in age-related diseases. Insights into the senescent phenotype have led to the development of novel therapeutic strategies, collectively known as senotherapies, that aim to ameliorate the detrimental effects of senescent cell accumulation in tissues. The senotherapeutic field has rapidly evolved over the past decade, with clinical translation of the first drugs discovered currently underway. What began as the straightforward removal of senescent cells using repurposed compounds, which were given the name of senolytics, has grown into an expanding field that uses different state of the art approaches to achieve the goal of preventing the build-up of senescent cells in the body. Here, we summarize the emergence of a new generation of senotherapies, based on improving the efficacy and safety of the original senolytics by making them targeted, but also branching out into drugs that prevent senescence (senoblockers) or revert it (senoreversers).The use of nanotechnology, specific antibodies, cell-based approaches and restored immunosurveillance is likely to revolutionize the field of senotherapies in the near future, hopefully allowing it to realize its full clinical potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mechanisms of Cancer and Ageing Laboratory, Barcelona, Spain.
- Department of Molecular and Cell Biology, University of Leicester, Leicester, U.K.
- The Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, U.K.
- Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
- FoodLab, Faculty of Health Sciences, Universitat Oberta de Catalunya, Barcelona, Spain.
ORCID-Profile: Salvador Macip
Zitieren
APA
Dhokia, V., Albati, A., Smith, H., Thomas, G., & Macip, S. (2024). A second generation of senotherapies: the development of targeted senolytics, senoblockers and senoreversers for healthy ageing. Biochemical Society Transactions, 52(4), 1661-1671. https://doi.org/10.1042/bst20231066
Vancouver
Dhokia V, Albati A, Smith H, Thomas G, Macip S. A second generation of senotherapies: the development of targeted senolytics, senoblockers and senoreversers for healthy ageing. Biochemical Society Transactions. 2024;52(4):1661-1671. doi:10.1042/bst20231066
BibTeX
@article{Dhokia2024,
author = {Dhokia, Vinesh and Albati, Amal and Smith, Hannah and Thomas, Gethin and Macip, Salvador},
title = {A second generation of senotherapies: the development of targeted senolytics, senoblockers and senoreversers for healthy ageing},
journal = {Biochemical Society Transactions},
year = {2024},
volume = {52},
number = {4},
pages = {1661--1671},
doi = {10.1042/bst20231066}
}
EUVIMED